
This AOP is licensed under a Creative Commons Attribution 4.0 International License.
Aop: 169
Title
GnRH pulse disruption leading to pituitary adenomas and carcinomas in the SD rat.
Short name
Graphical Representation
Point of Contact
Contributors
- Charles Wood
Status
Author status | OECD status | OECD project | SAAOP status |
---|---|---|---|
Under Development: Contributions and Comments Welcome | 1.29 | Under Development |
This AOP was last modified on June 04, 2021 13:38
Revision dates for related pages
Page | Revision Date/Time |
---|---|
Decreased, GnRH pulsatility/release in hypothalamus | September 16, 2017 10:17 |
Decreased, LH Surge from anterior pituitary | December 03, 2016 16:37 |
prolonged, estrus | December 03, 2016 16:37 |
interruption, Ovulation | December 03, 2016 16:37 |
Increased, circulating estrogen levels | December 03, 2016 16:37 |
Increased, lactotroph hyperplasia and hypertrophy | September 16, 2017 10:17 |
Increased, adenomas (pituitary) | September 16, 2017 10:17 |
Decreased, GnRH pulsatility/release in hypothalamus leads to Decreased, LH Surge from anterior pituitary | December 03, 2016 16:38 |
Decreased, LH Surge from anterior pituitary leads to prolonged, estrus | December 03, 2016 16:38 |
Decreased, LH Surge from anterior pituitary leads to interruption, Ovulation | December 03, 2016 16:38 |
prolonged, estrus leads to Increased, circulating estrogen levels | December 03, 2016 16:38 |
interruption, Ovulation leads to Increased, circulating estrogen levels | December 03, 2016 16:38 |
Increased, circulating estrogen levels leads to Increased, lactotroph hyperplasia and hypertrophy | December 03, 2016 16:38 |
Increased, lactotroph hyperplasia and hypertrophy leads to Increased, adenomas (pituitary) | December 03, 2016 16:38 |
atrazine | November 29, 2016 18:42 |
Abstract
This putative adverse outcome pathway (AOP) outlines potential key events leading to a tumor outcome in standard carcinogenicity models. This information is based largely on modes of action described previously in cited literature sources and is intended as a resource template for AOP development and data organization. Presentation in this Wiki does not indicate EPA acceptance of a particular pathway for a given reference agent, only that the information has been proposed in some manner. In addition, this putative AOP relates to the model species indicated and does not directly address issues of human relevance.
AOP Development Strategy
Context
Strategy
Summary of the AOP
Events:
Molecular Initiating Events (MIE)
Key Events (KE)
Adverse Outcomes (AO)
Type | Event ID | Title | Short name |
---|
KE | 1071 | Decreased, GnRH pulsatility/release in hypothalamus | Decreased, GnRH pulsatility/release in hypothalamus |
KE | 1072 | Decreased, LH Surge from anterior pituitary | Decreased, LH Surge from anterior pituitary |
KE | 1075 | prolonged, estrus | prolonged, estrus |
KE | 1074 | interruption, Ovulation | interruption, Ovulation |
KE | 1076 | Increased, circulating estrogen levels | Increased, circulating estrogen levels |
KE | 1081 | Increased, lactotroph hyperplasia and hypertrophy | Increased, lactotroph hyperplasia and hypertrophy |
AO | 1082 | Increased, adenomas (pituitary) | Increased, adenomas (pituitary) |
Relationships Between Two Key Events (Including MIEs and AOs)
Title | Adjacency | Evidence | Quantitative Understanding |
---|
Network View
Prototypical Stressors
Name |
---|
atrazine |
Life Stage Applicability
Taxonomic Applicability
Term | Scientific Term | Evidence | Link |
---|---|---|---|
SD rat | Rattus norvegicus | High | NCBI |
Sex Applicability
Sex | Evidence |
---|---|
Female | High |
Overall Assessment of the AOP
Domain of Applicability
Essentiality of the Key Events
Evidence Assessment
Known Modulating Factors
Quantitative Understanding
Considerations for Potential Applications of the AOP (optional)
References
1. O'Connor, J. C., Davis, L. G., Frame, S. R., and Cook, J. C. (2000). Detection of dopaminergic modulators in a tier I screening battery for identifying endocrine-active compounds (EACs). Reproductive toxicology 14(3), 193-205.